Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines

Cho, Hyun-Woong; Min, Kyung Jin; Kwon, Sang-Hoon; Kim, Kidong; Kim, Sung Hoon; Seong, Seok Ju; Song, Yong Jung; Lee, Keun Ho; Lee, Shin-Wha; Lee, Jeong‐Won; Ju, Woong; Kim, Young Tae; Lee, Jae Kwan

doi:10.3802/jgo.2021.32.e94

Cited by 5 publications

(3 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HPV infection rate in South Korea varies according to researchers, but is reported to be approximately 10%–15% [ 37 38 39 40 ]. HPV testing is used as a method for cervical cancer screening [ 41 ], and HPV vaccines are being used in clinical practice for cervical cancer prevention [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines

Yoo,

Lee,

Nam

et al. 2024

J Gynecol Oncol

Self Cite

View full text Add to dashboard Cite

This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were evaluated for their significance and impact on the current treatment and were finalized through voting by the development committee. The selected key questions were as follows: the efficacy and safety of immune checkpoint inhibitors as first- or second-line treatment for recurrent or metastatic cervical cancer; the oncologic safety of minimally invasive radical hysterectomy in early stage cervical cancer; the efficacy and safety of adjuvant systemic treatment after concurrent chemoradiotherapy in locally advanced cervical cancer; and the oncologic safety of sentinel lymph node mapping compared to pelvic lymph node dissection. The recommendations, directions, and strengths of this guideline were based on systematic reviews and meta-analyses, and were finally confirmed through public hearings and external reviews. In this study, we describe the revised practice guidelines for the management of cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines

Yoo,

Lee,

Nam

et al. 2024

J Gynecol Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…• The institution also indicates the vaccination of previously infected women, because there will be protection against future infections by subtypes other than the first infection [19] [20]. • Referenced country: United States.…”

Section: -Valentmentioning

confidence: 99%

HPV Vaccine: Integrative Review of National and International Guidelines

Filho¹,

Rocha²,

Bacha³

et al. 2022

Health

View full text Add to dashboard Cite

HPV (Human Papillomavirus) is an adenovirus of the Papillomaviridae family with approximately 200 subtypes (subdivided into low and high oncogenic risk groups), responsible for almost 99% of cervical cancers. Worldwide, there are more than 570,000 new cases and more than 311,000 women die each year from cervical cancer; for Brazil, the estimate is of more than 16,000 new cases per year. It is known that cervical cancer is one of the most easily preventable forms of cancer, as there is a highly effective vaccine against HPV. However, the morbidity and mortality rates correlated with human papillomavirus are still concerning, especially in less developed countries. In 2020, the WHO (World Health Organization) presented three goals to achieve by 2030 the worldwide extermination of cervical cancer; among these goals is vaccination. Is the world preparing for this battle? The present work is an integrative review, comparing national and international guidelines for HPV vaccination published in the last five years in the consulted databases, using the descriptors "cervical cancer", "prevention" and "guideline" and the boolean operator "and", from which nine articles were selected. The study made it possible to compare international and national guidelines for vaccination against HPV, showing that developed countries implemented the HPV vaccine longer ago and follow the WHO recommendations more rigorously and effectively than underdeveloped or developing countries. Adopting a single dose as a strategy, as suggested by the WHO in April 2022, could be an important step towards increasing coverage and providing protection for a greater number of girls who do not have access to HPV immunization.

show abstract

“…So, before administering a vaccination, clinicians must have a thorough discussion with their patients about the benefits of vaccination. More research is needed to assess the cost-effectiveness of immunisation among middle-aged women, as well as to recognise the women who would benefit from vaccination (8).…”

Section: Current Practice According To Clinical Guidelinesmentioning

confidence: 99%

Human papillomavirus infection

Das¹,

Khan²,

Shamshad³

et al. 2022

ijhs

View full text Add to dashboard Cite

In the past decade, cervical cancer has increased alarmingly in different parts of the world especially in developing regions. Cervical cancer is caused by persistent infection with high-risk HPV. Interestingly, HPV infection is associated with other cancers also besides cervical carcinoma. Therefore, a proper understanding of epidemiology, pathophysiology,and treatment and prevention strategy is required to combat this commonly occurring cancer. To eliminate cervical cancer from the global map the only strategy is rigorous vaccination in school-going teenage girls. The WHO wants to eliminate HPV by 2030. Its goal is to vaccinate 90% of females by 2025. However, proper awareness and government initiatives are far behind the required drive. Moreover, the low use of cervical cancer screening techniques like Pap smear and visual inspection with acetic acid hindered HPV infection and cervical cancer control in affected countries. In addition, we try to describe the whole pathological cycle of HPV in humans with prominent risk factors that can be a key to control the incidence of HPV-associated cancers. Finally, we showed the significance of the only available strategy to prevent HPV infection- i.e. vaccination.

show abstract

Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines

Cited by 5 publications

References 54 publications

Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines

Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines

HPV Vaccine: Integrative Review of National and International Guidelines

Human papillomavirus infection

Contact Info

Product

Resources

About